These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
449 related articles for article (PubMed ID: 28495497)
1. Risk for hepatitis B and C virus reactivation in patients with psoriasis on biologic therapies: A retrospective cohort study and systematic review of the literature. Snast I; Atzmony L; Braun M; Hodak E; Pavlovsky L J Am Acad Dermatol; 2017 Jul; 77(1):88-97.e5. PubMed ID: 28495497 [TBL] [Abstract][Full Text] [Related]
2. Hepatitis Virus Reactivation in Patients with Psoriasis Treated with Secukinumab in a Real-World Setting of Hepatitis B or Hepatitis C Infection. Megna M; Patruno C; Bongiorno MR; Gambardella A; Guarneri C; Romita P; Raimondo A; Loconsole F; Fabbrocini G Clin Drug Investig; 2022 Jun; 42(6):525-531. PubMed ID: 35633470 [TBL] [Abstract][Full Text] [Related]
3. Predictors of hepatitis B and C virus reactivation in patients with psoriasis treated with biologic agents: a 9-year multicenter cohort study. Chiu HY; Chiu YM; Chang Liao NF; Chi CC; Tsai TF; Hsieh CY; Hsieh TY; Lai KL; Chiu TM; Wu NL; Hui RC; Lee CN; Wang TS; Chen PH; Yang CC; Huang YH J Am Acad Dermatol; 2021 Aug; 85(2):337-344. PubMed ID: 31821860 [TBL] [Abstract][Full Text] [Related]
4. Managing Psoriasis in Patients with HBV or HCV Infection: Practical Considerations. Piaserico S; Messina F; Russo FP Am J Clin Dermatol; 2019 Dec; 20(6):829-845. PubMed ID: 31222626 [TBL] [Abstract][Full Text] [Related]
5. Safety Profile of Secukinumab in Treatment of Patients with Psoriasis and Concurrent Hepatitis B or C: A Multicentric Prospective Cohort Study. Chiu HY; Hui RC; Huang YH; Huang RY; Chen KL; Tsai YC; Lai PJ; Wang TS; Tsai TF Acta Derm Venereol; 2018 Oct; 98(9):829-834. PubMed ID: 29972221 [TBL] [Abstract][Full Text] [Related]
6. Risk of Reactivation of Hepatitis B Virus Infection in Psoriasis Patients Treated With Biologics: A Retrospective Analysis of 20 Cases From the BIOBADADERM Database. Sanz-Bueno J; Vanaclocha F; García-Doval I; Torrado R; Carretero G; Daudén E; Patricia Ruiz-Genao D; Alsina-Gibert MM; Pérez-Zafrilla B; Pérez-Rial G; Rivera R; Actas Dermosifiliogr; 2015; 106(6):477-82. PubMed ID: 25776200 [TBL] [Abstract][Full Text] [Related]
7. Risk of Hepatitis B Reactivation in Patients with Psoriasis on Ustekinumab. Ting SW; Chen YC; Huang YH Clin Drug Investig; 2018 Sep; 38(9):873-880. PubMed ID: 29968197 [TBL] [Abstract][Full Text] [Related]
8. Potential risk of HBV reactivation in patients with resolved HBV infection undergoing direct-acting antiviral treatment for HCV. Ogawa E; Furusyo N; Murata M; Toyoda K; Hayashi T; Ura K Liver Int; 2018 Jan; 38(1):76-83. PubMed ID: 28618152 [TBL] [Abstract][Full Text] [Related]
9. The safety profile of ustekinumab in the treatment of patients with psoriasis and concurrent hepatitis B or C. Chiu HY; Chen CH; Wu MS; Cheng YP; Tsai TF Br J Dermatol; 2013 Dec; 169(6):1295-303. PubMed ID: 23746170 [TBL] [Abstract][Full Text] [Related]
10. Reactivation of hepatitis B but not hepatitis C in patients with malignant lymphoma and immunosuppressive therapy. A prospective study in 305 patients. Markovic S; Drozina G; Vovk M; Fidler-Jenko M Hepatogastroenterology; 1999; 46(29):2925-30. PubMed ID: 10576374 [TBL] [Abstract][Full Text] [Related]
11. Hepatitis B virus reactivation among hepatitis C patients treated with direct-acting antiviral therapies in routine clinical practice. Loggi E; Gitto S; Galli S; Minichiello M; Conti F; Grandini E; Scuteri A; Vitale G; Di Donato R; Cursaro C; Furlini G; Andreone P J Clin Virol; 2017 Aug; 93():66-70. PubMed ID: 28654775 [TBL] [Abstract][Full Text] [Related]
12. Lack of evidence of viral reactivation in HBsAg-negative HBcAb-positive and HCV patients undergoing immunosuppressive therapy for psoriasis. Morisco F; Guarino M; La Bella S; Di Costanzo L; Caporaso N; Ayala F; Balato N BMC Gastroenterol; 2014 Dec; 14():214. PubMed ID: 25523080 [TBL] [Abstract][Full Text] [Related]
13. Reactivation rates of hepatitis B or C or HIV in patients with psoriasis using biological therapies: a systematic review and meta-analysis. Li L; Jiang X; Fu L; Zhang L; Feng Y Clin Exp Med; 2023 Jul; 23(3):701-715. PubMed ID: 35499793 [TBL] [Abstract][Full Text] [Related]
14. Hepatitis B Virus (HBV) Reactivation Following Pharmacological Eradication of Hepatitis C Virus (HCV). Pisaturo M; Macera M; Alessio L; Calò F; Coppola N Viruses; 2019 Sep; 11(9):. PubMed ID: 31540223 [TBL] [Abstract][Full Text] [Related]
15. Evaluation of hepatitis B reactivation among 62,920 veterans treated with oral hepatitis C antivirals. Belperio PS; Shahoumian TA; Mole LA; Backus LI Hepatology; 2017 Jul; 66(1):27-36. PubMed ID: 28240789 [TBL] [Abstract][Full Text] [Related]
16. Changes in hepatitis B virus surface antibody titer and risk of hepatitis B reactivation in HBsAg-negative/HBcAb-positive patients undergoing biologic therapy for rheumatic diseases: a prospective cohort study. Tien YC; Yen HH; Li CF; Liu MP; Hsue YT; Hung MH; Chiu YM Arthritis Res Ther; 2018 Nov; 20(1):246. PubMed ID: 30382902 [TBL] [Abstract][Full Text] [Related]
17. Risk of hepatitis B virus reactivation with direct-acting antivirals against hepatitis C virus: A cohort study from Egypt and meta-analysis of published data. El Kassas M; Shimakawa Y; Ali-Eldin Z; Funk AL; Wifi MN; Zaky S; El-Raey F; Esmat G; Fontanet A Liver Int; 2018 Dec; 38(12):2159-2169. PubMed ID: 29738637 [TBL] [Abstract][Full Text] [Related]
18. Differences in the patterns and outcomes of enhanced viral replication between hepatitis C virus and hepatitis B virus in patients with hepatocellular carcinoma during transarterial chemolipiodolization. Sung PS; Bae SH; Jang JW; Song DS; Kim HY; Yoo SH; Park CH; Kwon JH; Song MJ; You CR; Choi JY; Yoon SK Korean J Hepatol; 2011 Dec; 17(4):299-306. PubMed ID: 22310794 [TBL] [Abstract][Full Text] [Related]
19. Hepatitis B reactivation and outcomes in persons treated with directly acting antiviral agents against hepatitis C virus: results from ERCHIVES. Butt AA; Yan P; Shaikh OS; Abou-Samra AB Aliment Pharmacol Ther; 2018 Feb; 47(3):412-420. PubMed ID: 29181838 [TBL] [Abstract][Full Text] [Related]
20. High titers of anti-HBs prevent rituximab-related viral reactivation in resolved hepatitis B patient with non-Hodgkin's lymphoma. Cho Y; Yu SJ; Cho EJ; Lee JH; Kim TM; Heo DS; Kim YJ; Yoon JH J Med Virol; 2016 Jun; 88(6):1010-7. PubMed ID: 26531242 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]